Routine

Primary biliary cholangitis (PBC)

PBC, primary biliary cirrhosis, AMA, UDCA, cholestatic pruritus, obeticholic acid · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic autoimmune cholestatic liver disease with destruction of small intrahepatic bile ducts, typically middle-aged women. Presents with fatigue, pruritus, and cholestatic LFTs (raised ALP); diagnosed by anti-mitochondrial antibody (AMA) positivity. Untreated it progresses to cirrhosis. UDCA is first-line; biochemical response predicts outcome and guides second-line therapy.

Red flags

  • Jaundice / rising bilirubin (marker of progression and transplant need)
  • Decompensation: ascites, variceal bleed, encephalopathy
  • Intractable pruritus affecting quality of life
  • Features suggesting large-duct obstruction or PSC/cholangiocarcinoma
  • Overlap with autoimmune hepatitis (markedly raised transaminases/IgG)

Assessment

Differential diagnosis

  • Primary sclerosing cholangitis (large-duct, MRCP changes, IBD)
  • Autoimmune hepatitis / PBC-AIH overlap
  • Drug-induced cholestasis
  • Extrahepatic biliary obstruction (stone/stricture/tumour)
  • Sarcoidosis, IgG4-related cholangiopathy
  • MASLD, haemochromatosis (other raised-LFT causes)

Investigations

  • LFTs - cholestatic pattern (raised ALP and GGT, variable bilirubin)
  • Anti-mitochondrial antibody (AMA, esp. M2) - positive in ~95%; anti-sp100/gp210 if AMA negative
  • Immunoglobulins (raised IgM), ANA/SMA (exclude overlap)
  • Liver USS (exclude obstruction); MRCP if diagnostic doubt or to exclude PSC
  • FibroScan / consider biopsy if AMA negative or overlap suspected
  • Baseline: FBC, INR, calcium/vitamin D, TFTs (associated thyroid disease), lipids
  • Assess biochemical response (ALP, bilirubin) at 12 months on UDCA (e.g. POISE/Paris/Toronto criteria)

Management

  • Confirm diagnosis (2 of 3: cholestatic ALP, AMA positive, compatible histology) and exclude biliary obstruction
  • Start ursodeoxycholic acid (UDCA) weight-based first-line in ALL - improves biochemistry, survival and delays transplant
  • Treat pruritus (major quality-of-life issue): first-line cholestyramine, then rifampicin, then naltrexone/sertraline
  • Replace fat-soluble vitamins; manage associated osteoporosis (calcium/vitamin D, DEXA) and thyroid disease
  • Assess biochemical response to UDCA at 12 months (ALP and bilirubin)
  • Inadequate response or UDCA intolerance -> add second-line PPAR/other agent (obeticholic acid historically; elafibranor or seladelpar now preferred where available)
  • Screen for cirrhosis complications: varices, and HCC surveillance if cirrhosis
  • Refer for transplant assessment if progressive (rising bilirubin, decompensation, intractable pruritus)

Drugs & doses

Ursodeoxycholic acid (UDCA) 13-15 mg/kg/day PO (usually in divided doses) - first-line, continue indefinitely
Second-line for inadequate UDCA response/intolerance: elafibranor 80 mg PO once daily OR seladelpar 10 mg PO once daily (PPAR agonists, add-on or monotherapy) where available [verify local]
Obeticholic acid 5-10 mg PO once daily was a second-line option but WITHDRAWN from the US market in 2025 and restricted elsewhere - check current status [verify local]
Bezafibrate/fenofibrate as off-label second-line add-on (improves ALP and pruritus) per specialist [verify local]
Pruritus: cholestyramine 4 g PO once-four times daily (take separately from UDCA by >=4 h); then rifampicin 150-300 mg PO daily (monitor LFTs); then naltrexone or sertraline
Fat-soluble vitamin (A, D, E, K) replacement; calcium + vitamin D for bone protection
Avoid obeticholic acid in decompensated cirrhosis (hepatotoxicity)

Disposition

Outpatient hepatology. Admit for decompensation or intractable symptoms. Transplant referral for progressive disease, rising bilirubin, or intractable pruritus.

Complications & pitfalls

  • Cirrhosis, portal hypertension, decompensation
  • Fat-soluble vitamin deficiency and osteoporosis (metabolic bone disease)
  • Intractable pruritus and fatigue
  • Hepatocellular carcinoma (if cirrhosis)
  • Associated autoimmune disease (Sjogren, thyroid, coeliac), dyslipidaemia

Exam pearls

  • AASLD/EASL: diagnose PBC with 2 of 3 - cholestatic ALP, AMA positivity, and compatible histology; biopsy usually unnecessary if AMA positive with cholestatic LFTs.
  • UDCA 13-15 mg/kg/day is first-line for everyone; assess biochemical response (ALP/bilirubin) at 12 months - response strongly predicts transplant-free survival.
  • For inadequate UDCA response, PPAR agonists (elafibranor, seladelpar) are now preferred second-line; obeticholic acid was withdrawn from the US market in 2025 - verify current availability. [verify local]
  • Pruritus ladder: cholestyramine (dose apart from UDCA) -> rifampicin -> naltrexone/sertraline; bezafibrate also helps pruritus.
  • Always protect bone (DEXA, calcium/vitamin D) and replace fat-soluble vitamins; screen for coexisting autoimmune disease.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.